Gut bacteria supplements eased low mood and anxiety across 72 trials

Conventional treatments for anxiety and depression have recognised limitations, which has fed growing interest in alternative and adjunct approaches. Among the most talked about are supplements that target the gut: probiotics, which are live microbes; prebiotics, which feed them; and synbiotics, which combine the two. Individual trials of these products on mood, anxiety and sleep have produced inconsistent results, leaving readers and clinicians unsure whether there is a real signal underneath. This review set out to pool every randomised trial and settle whether these gut-targeted supplements actually move the needle.

The researchers systematically searched PubMed, Web of Science and Embase from inception to October 2023, with an update in March 2025, for randomised controlled trials. Included studies covered people with anxiety and depression disorders, as well as chronic disease patients and healthy populations with depressive or anxiety symptoms. In total 72 trials were pooled, covering 3,319 intervention and 2,778 control participants. Depression was examined in 63 studies, anxiety in 49, and sleep in 12 studies that used probiotic interventions. Two researchers independently screened and extracted the data, and study quality was rated with the Cochrane risk of bias tool.

Compared with placebo, the supplements were associated with significant reductions in depression scores and in anxiety scores, both of moderate size in statistical terms. Probiotics were also shown to improve sleep quality. Subgroup analyses indicated that probiotics, prebiotics and synbiotics each independently alleviated anxiety and depression, so the effect was not confined to one product type. The impact of probiotics varied by population, by how long the intervention lasted, and by the type of probiotic used, which suggests the details of the product and the person taking it both matter.

Previous research in this area has been openly inconsistent, which is precisely why this pooling was done, and the overall picture it paints is more positive than sceptics might expect. That said, the authors flag high heterogeneity, meaning the trials disagreed with each other substantially, and limited methodological quality across the included studies. Both problems tend to inflate apparent benefits. The conclusion is framed as promise rather than proof: these supplements look like plausible adjunctive options, but large, high-quality trials with long-term follow-up are still needed to confirm the findings.

This is a reason to take the gut-brain connection seriously rather than dismiss it as marketing. Across a large body of trials, gut-targeted supplements were linked to modest improvements in mood, anxiety and sleep quality, and the benefit appeared across all three product categories. It is equally a reason for measured expectations: the effects were moderate, the underlying studies were uneven in quality, and the results varied depending on who was taking the supplement and for how long. Nothing here positions these products as a replacement for established treatment; the evidence discussed them as adjuncts.